Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer-Reference-Cited by-同舟云学术

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer

Published:2017-12 Issue:1 Volume:15 Page:
ISSN:1478-811X
Container-title:Cell Communication and Signaling
language:en
Short-container-title:Cell Commun Signal

Author:

Ferrari Nicoletta,Granata Ilaria,Capaia Matteo,Piccirillo Marina,Guarracino Mario Rosario,Venè Roberta,Brizzolara Antonella,Petretto Andrea,Inglese Elvira,Morini Martina,Astigiano Simonetta,Amaro Adriana Agnese,Boccardo Francesco,Balbi Cecilia,Barboro Paola^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

http://link.springer.com/content/pdf/10.1186/s12964-017-0206-x.pdf

Reference47 articles.

1. Pelekanou V, Castanas E. Androgen control in prostate cancer. J Cell Biochem. 2016;117:2224–34.

2. Sittadjody S, Thangasamy T, NickKolgh B, Balaji KC. Non-androgen signaling pathways in castration-resistant prostate cancer. In: Balaji K, editor. Managing metastatic prostate cancer in your urological oncology practice. Cham: Springer; 2016. p. 35–63. https://doi.org/10.1007/978-3-319-31341-2_4 .

3. Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M, Rocchi P. The hallmarks of castration-resistant prostate cancers. Cancer Treat Rev. 2015;41:588–97.

4. Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 2016;7:64447–70.

5. Wyatt AW, Mo F, Wang K, McConeghy B, Brahmbhatt S, Jong L, Mitchell DM, Johnston RL, Haegert A, Li E, et al. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol. 2014;15:426.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functionality of BRCA1 supports the survival of prostate cancer cells during the development of castration resistance;2024-06-23

2. RNA m6a Methylation Regulator Expression in Castration-Resistant Prostate Cancer Progression and Its Genetic Associations;Cancers;2024-03-27

3. Identification of Molecular Markers Associated with Prostate Cancer Subtypes: An Integrative Bioinformatics Approach;Biomolecules;2024-01-10

4. Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology;Frontiers in Pharmacology;2024-01-03

5. Resistance of prostate cancer to topoisomerase inhibitors;Therapy Resistance in Prostate Cancer;2024